This registry study will evaluate patients with metastatic brain tumors undergoing, or having undergone, stereotactic radiosurgery (SRS) at Swedish Medical Center. Clinical outcomes will be evaluated at the 3, 6 and 12-month time points. Clinical data, SRS treatment data, and imaging data (including anatomic and advanced imaging sequences obtained prior to and serially following SRS) will be archived in an online informatics platform, specifically a metastatic brain tumor registry known as the Comprehensive Neuro-oncology Data Repository for Metastatic Tumors (CONDR - Mets).
Study Type
OBSERVATIONAL
Enrollment
100
Swedish Medical Center
Seattle, Washington, United States
Quantitative measures of overall tumor volume will be performed for each subject at the time of SRS
Time frame: At the time of SRS
Quantitative measures of tumor number will be performed for each subject at the time of SRS
Time frame: At the time of SRS
Overall survival will be measured for each subject (in weeks from SRS to death)
Time frame: Post-SRS
Measures of ADC, rCBV, MTT and ktrans will be performed for each treated tumor at treatment and at 6 months following SRS
Time frame: 6 months post SRS
Time to progression (in weeks) will be measured for each treated tumor
Time frame: Post-SRS
Diagnosis of progression or radiation necrosis (made on clinical reflection at study's end) will be determined for tumors where diagnosis is in question at 6 and 12 months after SRS
Time frame: 12 months post-SRS
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.